Immunicon Congratulates Dr. Daniel Hayes on Winning ASCO's Inaugural Gianni Bonadonna Breast Cancer Award

Immunicon Corporation (NASDAQ-GM:IMMC) congratulates Daniel F. Hayes, MD, professor of internal medicine and Clinical Director of the Breast Oncology Program at the University of Michigan Comprehensive Cancer Center, for receiving the inaugural American Society of Clinical Oncology (ASCO) and The ASCO Foundation's Gianni Bonadonna Breast Cancer Award and Fellowship. The annual $10,000 award, presented at the September 7-8 Breast Cancer Symposium in San Francisco, recognizes an active clinical or translational researcher with a distinguished record of accomplishments in advancing the field of breast cancer. Among his many research accomplishments, Dr. Hayes has been a major force in the clinical application of the CellSearch™ Circulating Tumor Cell Test, developed by Immunicon Corporation and marketed by Veridex LLC, a Johnson & Johnson company. In 2004, his research was among those published in The New England Journal of Medicine that had a direct impact on CellSearch's FDA Clearance. Dr. Hayes continues to conduct clinical trials and research to discover how best to integrate the knowledge gained from leveraging circulating tumor cells in the treatment of patients with metastatic breast cancer. Byron D. Hewett, President and Chief Executive Officer of Immunicon commented, "Dr. Hayes has been a pioneering force in circulating tumor cell research. His leadership in clinical trials is helping to translate this important technology to the clinical setting.” The Gianni Bonadonna Award is accompanied by a one-year, $50,000 Fellowship Grant that will be awarded by The ASCO Foundation to an early-career breast cancer researcher who will work in the lab at the recipient's institution. ASCO is the world's leading professional organization representing physicians of all oncology subspecialties who care for people with cancer. For more about the award, visit www.asco.org. About Immunicon Corporation Immunicon Corporation is developing and commercializing proprietary cell- and molecular-based human diagnostic and life science research products with an initial focus on cancer disease management. Immunicon has developed platform technologies for selection and analysis of rare cells in blood, such as circulating tumor cells and circulating endothelial cells that are important in many diseases and biological processes. Immunicon’s products and underlying technology platforms also have application in the clinical development of cancer drugs and in cancer research and may have applications in other fields of medicine, such as cardiovascular and infectious diseases. For more information, please visit www.immunicon.com. Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often preceded by words such as "hope,” "may,” "believe,” "anticipate,” "plan,” "expect,” "intend,” "assume,” "will” and similar expressions. Forward-looking statements contained in this press release include, among others, statements regarding the anticipated clinical utility of Immunicon’s products and services and other statements not of historical fact. Immunicon cautions investors not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release, are based on the current expectations and intent of the management of Immunicon and involve certain factors, such as risks and uncertainties that may cause actual results to be far different from those suggested by these statements. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict, including, but not limited to, risks and uncertainties associated with: Immunicon’s dependence on Veridex, LLC, a Johnson & Johnson company, in the field of cancer cell analysis; the ability to earn license and milestone payments under Immunicon’s agreement with Veridex; Immunicon’s capital and financing needs; research and development and clinical trial expenditures; commercialization of product candidates; Immunicon’s ability to obtain licenses from third parties to commercialize products; Immunicon’s ability to manage its growth; obtaining necessary regulatory approvals; reliance on third party manufacturers and suppliers; reimbursement by third party payors to Immunicon’s customers; compliance with applicable manufacturing standards; retaining key personnel; delays in the development of new products or planned improvements to products; effectiveness of products compared to competitors’ products; protection of Immunicon’s intellectual property; conflicts with third party intellectual property; product liability lawsuits that may be brought against Immunicon; labor, contract or technical difficulties; and competitive pressures in Immunicon’s industry. These factors are discussed in more detail in Immunicon’s filings with the Securities and Exchange Commission. Except as required by law, Immunicon accepts no responsibility for updating the information contained in this press release beyond the published date, whether as a result of new information, future events or otherwise, or for modifications made to this document by Internet or wire services. "Immunicon” and the Immunicon Corporation logo are registered trademarks of Immunicon Corporation. ALL RIGHTS RESERVED.